The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation
Authors:
- 1 December 2016
- journal article
- research article
- Published by Elsevier in Journal of Critical Care
- Vol. 36, 29-34
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2015
- Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic ratsThrombosis Research, 2014
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*Critical Care Medicine, 2013
- Expert consensus for the treatment of disseminated intravascular coagulation in JapanThrombosis Research, 2010
- Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis modelCritical Care, 2009
- Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trialJournal of Thrombosis and Haemostasis, 2006
- Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulationJournal of Thrombosis and Haemostasis, 2006
- Pathogenesis and treatment of disseminated intravascular coagulation in the septic patientJournal of Critical Care, 2001
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- The Inhibitory Effect of Recombinant Human Soluble Thrombomodulin on Initiation and Extension of CoagulationThrombosis and Haemostasis, 1999